{ "docId": "019de073-a7b5-7720-904b-d55cb9d2acd2", "docSlug": "ff09795c4205ae982e453519f0f2447b", "documentTitle": "Bionomics | Investor Presentation Deck | 59 slides", "authorId": "bionomics", "authorName": "Bionomics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 53, "pageCount": 59, "prevPage": 52, "nextPage": 54, "slideType": "testimonial", "function": "show_traction", "density": "overcrowded", "nDataPoints": 1, "notes": "Includes qualitative feedback from psychiatrists alongside key findings.", "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de073-a7b5-7720-904b-d55cb9d2acd2/53", "deckHref": "/decks/019de073-a7b5-7720-904b-d55cb9d2acd2", "deckJsonHref": "/decks/019de073-a7b5-7720-904b-d55cb9d2acd2.json", "deckAnchorHref": "/decks/019de073-a7b5-7720-904b-d55cb9d2acd2#slide-53", "components": [ { "bbox": { "h": 0.68, "w": 0.52, "x": 0.04, "y": 0.22 }, "kind": "list", "text": "Physicians are desperate for innovation in anxiety and are highly enthusiastic about having a novel mechanism of action. They are less focused on the specifics of the 210 MOA and rather focus on the fact that it is not another 'me too' SSRI or benzo.\nThe clean safety and side-effect profile of BNC210 is a strong differentiator from all currently approved SAD drug classes.\nThe PRN efficacy of BNC210 being similar to benzos is encouraging to physicians, as benzos are viewed as highly effective in social anxiety.\nRapid onset of action is viewed as a strong positive as benzos are the only products that work on traditional social anxiety (as opposed to performance-specific issues). SSRIs take 6 or more weeks to become effective.\nOne KOL commented that BNC210 has solid proof of concept data from imaging studies, which in his opinion demonstrate strong anxiolytic activity.", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "46c08889-0b31-47d7-aaf0-acfe212082cc", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.34, "x": 0.62, "y": 0.4 }, "kind": "quote", "text": "\"This seems positive. It's everything I told you that I wanted.\" - Psychiatrist, MI", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "386645f7-783c-445a-bd91-c65b34b374c4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.13, "w": 0.34, "x": 0.62, "y": 0.23 }, "kind": "quote", "text": "\"This product is interesting because it has a unique MOA, and it is not another 'me too' SSRI or benzo. No substance use is a big plus.\" - Psychiatrist, TX", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "58499235-1027-4662-80af-812708f12a9d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.13, "w": 0.34, "x": 0.62, "y": 0.73 }, "kind": "quote", "text": "\"Finally we could have something new to offer to our patients! The last thing we had was buspar in the 80's. No one is touching anxiety, and it's huge.\" - Psychiatrist, TN", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c3c20e7f-098e-4a6a-884f-cdcde0094637", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.34, "x": 0.62, "y": 0.53 }, "kind": "quote", "text": "\"This is a totally different MOA. I think we have 12 SSRIs already. Product X seems like a slam dunk with no issues related to withdrawal or sedation.\" - Psychiatrist, MD", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e9fe7f0b-330b-47dc-98cd-9bd13356f51d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.33, "x": 0.15, "y": 0.97 }, "kind": "source-note", "text": "Source: Bluestar Primary Physician Interviews (n=13, March 2022)", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9f50edd4-8162-4184-9d0b-eff685f9b1ce", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "Psychiatrists interviewed are highly enthusiastic about the blinded BNC210 product profile, as it is an innovative therapy offering benefits on safety and efficacy", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7efceb2c-d5c0-430a-98f5-f320f9b6fea6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.36, "x": 0.32, "y": 0.15 }, "kind": "title", "text": "BNC210 Social Anxiety Disorder TPP Reaction", "attrs": null, "subkind": "subtitle", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "45234e23-e6a3-415f-ba99-e5fd1b23a074", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Audience Definition", "slug": "audience-definition", "agent": "Storyteller", "layer": "slide", "matchId": "9d293078-987b-4172-be2d-2e34fa274464", "evidence": "Source: Bluestar Primary Physician Interviews (n=13, March 2022)", "confidence": 0.7 } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 53, "from": 52, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "22404f9e-d53d-41a1-8a07-47dad47915ff", "evidence": "The deck presents the shortcomings of existing treatments for SAD, including side effects and limited efficacy.", "position": 0, "objective": "Highlight the limitations and risks of current treatments for SAD", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }